Entries |
Document | Title | Date |
20080221141 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency - Spirocyclic cyclohexane compounds useful in pharmaceutical compositions for use in the treatment of substance dependency. | 09-11-2008 |
20080255173 | Novel Specific Caspase-10 Inhibitors - The invention relates to compounds of the general formula (I), and to their use as caspase-10 inhibitors, especially for the treatment of diabetic retinopathy. | 10-16-2008 |
20080262011 | Modulator - The present invention relates to a compound of formula I, or a pharmaceutically acceptable salt thereof. Formula (I), wherein R | 10-23-2008 |
20080293752 | Antiseptic body glide - An antiseptic body glide is a body glide with antiseptic properties. The antiseptic components do not interfere with other body glide components such as lubricants or preservatives. Additionally, the antiseptic body glide does not react unfavorably with latex. The antiseptic components do not have a bad taste or react with the other components to produce a bad taste. As such, the antiseptic body glide enhances intimate activities without compromising those activities in any way. | 11-27-2008 |
20090062321 | Hydroxybenzoate Salts Of Metanicotine Compounds - Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form. | 03-05-2009 |
20090069361 | METHODS OF TREATMENT USING (+)- ISOPROPYL 2-METHOXYETHYL 4-(2-CHLORO-3-CYANO-PHENYL)-1, 4-DIHYDRO-2, 6-DIMETHYL-PYRIDINE-3, 5-DICARBOXYLATE - The present invention relates to methods of treatment using the compound (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate, as a sole active agent or in combination with other pharmacological agents. | 03-12-2009 |
20090076048 | DEUTERIUM-ENRICHED XALIPRODEN - The present application describes deuterium-enriched xaliproden, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20090105288 | CARBON LINKED MODULATORS OF gamma-SECRETASE - The present invention relates to compounds of Formula I as shown below, wherein the definitions of A, X, R | 04-23-2009 |
20090118317 | Statin-Carboxyalkylether Combinations - The invention is a pharmaceutical composition comprising a carboxyalkylether which lowers triglycerides and elevated HDL, and a statin which inhibits HMG-CoA reductase, thereby reducing LDL, said composition being useful for treating vascular diseases. | 05-07-2009 |
20090163526 | Process for the Preparation of an Anti Microbial Extract from Leaves of the Plant Callistemon Rigidus - A process for the preparation of an antimicrobial extract from leaves of the plant | 06-25-2009 |
20090170886 | ANDROGEN MODULATORS - The present invention is directed to a new class of benzonitriles and to their use as androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease excess sebum secretions and to stimulate hair growth. | 07-02-2009 |
20090176814 | COMBINATIONS OF POTASSIUM CHANNEL OPENERS AND SODIUM CHANNEL INHIBITORS OR SODIUM CHANNEL-INFLUENCING ACTIVE COMPOUNDS FOR TREATING PAINS - The invention relates to pharmaceutical combinations of potassium channel openers and sodium channel inhibitors. for treating pains which are accompanied by an increase in muscle tone. | 07-09-2009 |
20090239888 | Methods for Inhibiting Amyloid Precursor Protein and Beta-Amyloid Production and Accumulation - Compositions and uses of mGluR | 09-24-2009 |
20090258889 | PESTICIDAL COMPOSITIONS - The present disclosure relates to pesticidal compositions and to methods for controlling pests such as insects and other arthropods. More particularly, the disclosure relates to a pesticidal compositions containing mineral oil and one or more additional components which, when used in combination, act synergistically to control insect and pest populations. | 10-15-2009 |
20090264453 | GENETIC POLYMORPHISMS ASSOCIATED WITH CORONARY HEART DISEASE, METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with coronary heart disease, and in particular MI, and response to drug treatment. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. | 10-22-2009 |
20090275601 | Novel Pyriproxyfen Compositions - New pesticidal compositions comprising pyriproxyfen and methyl esters of C | 11-05-2009 |
20090312354 | DHA Esters and Use Thereof In Treatment and Prevention of Cardiovascular Disease - The present invention relates to a docosahexaenoic acid ester with an alcohol chosen among the group-B vitamins or provitamins, advantageously comprised by: nicotinyl alcohol of the following formula (I), panthenol of the following formula (II), and inositol of the following formula (III) or with isosorbide of the following formula (IV) or isosorbide mononitrate of the following formula (V). It also relates to a method of preparation of same, a pharmaceutical composition comprising same and the use of same in the treatment or prevention of cardiovascular disease, in particular auricular fibrillation. | 12-17-2009 |
20090312355 | Non-Flushing Niacin Analogues, and Methods of Use Thereof - One aspect of the present invention relates to substituted pyridines and pharmaceutically acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the invention relates to a pharmaceutical composition, comprising a compound of the present invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. The present invention also relates to methods of treating a range of mammalian maladies or conditions, including but not limited to hyperlipidemia, hypercholesterolemia, atherosclerosis, coronary artery disease, congestive heart failure, cardiovascular disease, hypertension, coronary heart disease, angina, pellagra, Hartnup's syndrome, carcinoid syndrome, arterial occlusive disease, obesity, hypothyroidism, vasoconstriction, osteoarthritis, rheumatoid arthritis, diabetes, Alzheimer's disease, lipodystrophy, or dyslipidemia, raising serum high-density lipoprotein (HDL) levels, and lowering serum low-density lipoprotein (LDL) levels. | 12-17-2009 |
20090318485 | NOVEL INHIBITORS OF RHO KINASE - The present invention relates to compounds and methods which may be useful as inhibitors of Rho kinase for the treatment or prevention of disease. | 12-24-2009 |
20100010027 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE - The present invention provides a method of treating glaucoma or ocular hypertension which comprises applying to the eye of a person in need thereof an amount sufficient to treat glaucoma or ocular hypertension of a compound of formula I | 01-14-2010 |
20100016346 | ELASMOBRANCH-REPELLING DOMPOUNDS AND METHODS OF USE - Compounds for repelling elasmobranch having an aldehyde or derivative, a carboxylic acid a derivative, a ketone or a derivative thereof, a di-ketone or a derivative thereof, a pyridine or derivative thereof, or an antipyrine or a derivative thereof and methods of use thereof. | 01-21-2010 |
20100016347 | SERIES OF SKIN WHITENING (LIGHTENING) COMPOUNDS - The present invention is directed to inhibitors of tyrosinase, pharmaceutical compositions comprising such tyrosinase inhibitors, and methods of making and using the same. Specifically, included in the present invention are compositions of matter comprised of at least one 2,4-dihydroxybenzene analog, which inhibit the activity of tyrosinase and which inhibit the overproduction of melanin. | 01-21-2010 |
20100022570 | NOVEL MICROBIOCIDES - Compounds of the formula (I) in which the substituents are as defined in claim | 01-28-2010 |
20100035908 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS - The present invention relates to a compound according to formula: (I); wherein X | 02-11-2010 |
20100087468 | MODULATORS OF PPAR AND METHODS OF THEIR PREPARATION - The present invention is directed to certain novel compounds represented by Formula (I) and pharmaceutically acceptable salts, solvates, hydrates and prodrugs thereof. The present invention is also directed to methods of making and using such compounds and pharmaceutical compositions containing such compounds to treat or control a number of diseases mediated by PPAR such as glucose metabolism, lipid metabolism and insulin secretion, specifically Type 2 diabetes, hyperinsulinemia, hyperlipidemia, hyperuricemia, hypercholesteremia, atherosclerosis, one or more risk factors for cardiovascular disease, Syndrome X, hypertriglyceridemia, hyperglycemia, obesity and eating disorders. | 04-08-2010 |
20100137346 | DESFERRITHIOCIN ANALOGUE ACTINIDE DECORPORATION AGENTS - A pharmaceutical composition comprising a non-toxic effective amount of an actinide decorporation agent and a pharmaceutically acceptable carrier therefore, the actinide decorporation agent comprising a hexacoordinate desferrithiocin analogue capable of chelating an actinide in vivo and a method for removing an actinide from the tissue of a human or nonhuman mammal. | 06-03-2010 |
20100137347 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS - Disclosed herein is a compound of the formula (I). Therapeutic methods, compositions, and medicaments, related thereto are also disclosed. | 06-03-2010 |
20100152220 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS - Compounds of formula (Ia): | 06-17-2010 |
20100197712 | USE OF DOPAMINE STABILIZERS - At least one embodiment of the present invention relates to the use of a dopamine stabilizing substance in an oral, subcutaneous or intramuscular daily dose of 1-20 mg or in an intravenous daily dose of 0.1-2 mg in treatment of a neurological or psychiatric disorder characterized by a hypofunction of the dopamine system. At least one embodiment of the invention also relates to the use of a dopamine stabilizing substance in an oral, subcutaneous or intramuscular daily dose of 25-50 mg in treatment of a disorder caused by instability of neural circuits. | 08-05-2010 |
20100197713 | BUTONE DERIVATIVES USEFUL AS COOLING AGENTS - Cooling compounds of formula (I) wherein R | 08-05-2010 |
20100204256 | 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS - 1-Phenyl-2-pyridinyl alkyl alcohol compounds are effective as inhibitors of the phosphodiesterase 4 (PDE4) enzyme and may be used to prevent and/or treat certain diseases or conditions. | 08-12-2010 |
20100249165 | PDZ DOMAIN MODULATORS - This invention relates to compounds useful as PDZ domain modulators, in particular the PDZ domain of PICK1. | 09-30-2010 |
20100249166 | DIFFERENTIAL EVAPORATION POTENTIATED DISINFECTANT SYSTEM - Antimicrobial compositions and methods of using such antimicrobial compositions to provide a reduction in populations of viable microorganisms. | 09-30-2010 |
20100298367 | Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders - The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I or the general formula III: | 11-25-2010 |
20110009439 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS - Compounds of formula (Ia): | 01-13-2011 |
20110028504 | Formulation of radioprotective alpha beta unsaturated aryl sulfones - A pharmaceutical composition is provided for administration prior to or after exposure to ionizing radiation for reducing toxic effects of the radiation in a subject. An effective amount of the pharmaceutical composition provided comprising an effective amount of at least one radioprotective α, β unsaturated aryl sulfone, and at least one component selected from the group consisting of a) at least one water soluble polymer in an amount between about 0.5% and about 90% w/v, b) at least one chemically modified cyclodextrin in an amount between about 20% and about 60% w/v, and c) DMA in an amount between about 10% and about 50% w/v. | 02-03-2011 |
20110082166 | NOVEL 4-BENZHYDRYL-TETRAHYDRO-PYRIDINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS - This invention relates to novel 4-benzhydryl-tetrahydro-pyridine derivatives of Formula (I), any of its stereoisomers or any mixture of its stereoisomers, or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, wherein R | 04-07-2011 |
20110105544 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER - The invention provides novel compounds of formula (I), wherein: R | 05-05-2011 |
20110105545 | GPBP inhibition using Q2 peptidomimetics - Disclosed are compounds of formula: | 05-05-2011 |
20110172258 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS - Compounds of formula (Ia): | 07-14-2011 |
20110237613 | DHA ESTERS AND USE THEREOF IN TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE - The present invention relates to a docosahexaenoic acid ester with an alcohol chosen among the group-B vitamins or provitamins, advantageously comprised by: nicotinyl alcohol of the following formula (I), panthenol of the following formula (II), and inositol of the following formula (III) or with isosorbide of the following formula (IV) or isosorbide mononitrate of the following formula (V). It also relates to a method of preparation of same, a pharmaceutical composition comprising same and the use of same in the treatment or prevention of cardiovascular disease, in particular auricular fibrillation. | 09-29-2011 |
20110269786 | TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME IN DIABETIC PATIENTS USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES - Administration of sPLA | 11-03-2011 |
20120088784 | Substituted Aromatic Compounds and Pharmaceutical Uses thereof - The present invention relates to substituted aromatic compounds of Formula I and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds in the prevention and/or treatment of various diseases and conditions in subjects, including the prevention or treatment of (i) blood disorders, (ii) renal disorders, a nephropathies, or renal disorder complications; (iii) inflammatory-related diseases; and/or (iv) oxidative stress related disorders. | 04-12-2012 |
20120122908 | Novel C-4 Substituted Retinoids - C-4 substituted retinoic acid analogs, synthesis methods of C-4 substituted retinoic acid analogs and methods of using C-4 substituted retinoic acid analogs to treat various cancers and dermatological diseases and conditions. The C-4 substituted retinoic acid analogs include C-4 all-trans retinoic acid (ATRA) and 13-cis retinoic acid (13-CRA) analogs. The C-4 substituted retinoic acid analogs inhibit all-trans retinoic acid (ATRA) 4-hydroxylase activity, thereby inhibiting the catabolism of ATRA. The C-4 substituted retinoic acid analogs also have ATRA-mimetic activity. The preferred substitutions at C-4 are an azole group, a sulfur, oxygen, or nitrogen containing group, a pyridyl group, an ethinyl group, a cyclopropyl-amine group, an ester group, or a cyano group, or forms, together with the C-4 carbon atom, an oxime, an oxirane or aziridine group. | 05-17-2012 |
20130210849 | Methods for treating disorders associated with mGLU receptors including addiction and depression - Methods are provided for treating disorders associated with mGlu receptors by simultaneously inhibiting at least two mGluRs belonging to at least two different groups. In one embodiment, there are provided methods for treating a disorder associated with mGlu receptors 2, 3, and 5, including administering to a subject in need thereof an effective amount of at least one antagonist which modulates mGluR2, mGluR3, and mGluR5. The disorders treated by the method include, for example, nicotine addiction, cocaine addiction, and depression. | 08-15-2013 |
20130225623 | Methods of Treating Psychiatric or Neurological Disorders with MGLUR Antagonists - Methods for treating a psychiatric or neurological disease or disorder using combinations of Group 1 mGluR antagonists are disclosed. In certain aspects, these methods include the treatment of a patient having a neurological or psychiatric disease or disorder associated with a CYFIP1 gene change. | 08-29-2013 |
20130245053 | Pesticidal Compositions - The present disclosure relates to pesticidal compositions and to methods for controlling pests such as insects and other arthropods. More particularly, the disclosure relates to a pesticidal compositions containing mineral oil and one or more additional components which, when used in combination, act synergistically to control insect and pest populations. | 09-19-2013 |
20140011826 | METABOTROPIC GLUTAMATE RECEPTOR GROUP I ANTAGONISTS FOR TREATMENT OF ABNORMAL UNION OF TISSUE - Use of a metabotropic glutamate receptor group I antagonist, or a pharmaceutically acceptable salt, prodrug or an optical isomer thereof, for the manufacture of a medicament for the treatment or the prevention of abnormal union of tissue, is provided. A related method is also provided. | 01-09-2014 |
20140080852 | GPBP inhibition using Q2 peptidomimetics - Disclosed are compounds of formula: | 03-20-2014 |
20140088127 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES - A novel process for preparing thiazolidinediones, preferably Pioglitazone, as described. Also described are novel intermediates involved in its synthesis and process for their preparation and use in medicine. | 03-27-2014 |
20140179722 | Antiperspirant and Deodorant Compositions - The present application relates to personal care compositions comprising perfumes and non-sulfur-based perfume raw materials, and methods for making and using the personal care compositions to resist consumer fragrance habituation. | 06-26-2014 |
20140179723 | LOCAL COCHLEAR APPLICATION OF STATINS FOR STIMULATING NEURITE REGROWTH IN THE COCHLEA - Statin compositions are disclosed for stimulating neurite growth from spiral ganglion neurons in the inner ear and methods for preventing damage to or treating damage of auditory neurons and/or hair cells of the cochlea following acoustic or toxic insult. | 06-26-2014 |
20140323510 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS - Disclosed herein is a compound of the formula | 10-30-2014 |
20140371252 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS - Processes for making and using compounds of formula (I): | 12-18-2014 |
20140378494 | Pesticidal Mixtures Comprising Cyanosulfoximine Compounds - The invention relates to pesticidal mixtures comprising as active compounds
| 12-25-2014 |
20150148362 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE - The present invention relates to a pharmaceutical composition or a functional health food comprising a verbenone derivative and pharmaceutically acceptable salts thereof as active ingredients for treating or preventing a neurodegenerative disease. More specifically, the verbenone derivative according to the present invention reduces neuronal cell death and oxidative stress, and is highly effective in preventing ischemic brain damage and inflammatory cell migration in rats, thereby providing the pharmaceutical composition or the functional health food which is useful in treating neurodegenerative diseases. | 05-28-2015 |
20150306056 | USE OF A DHA ESTER FOR PROPHYLACTIC AND/OR CURATIVE TREATMENT OF DREPANOCYTOSIS - The present invention relates to a docosahexaenoic acid ester including an alcohol selected from among the group made up of nicotinol, panthenol, inositol, isosorbide, and isosorbide mononitrate, or one of the pharmaceutically acceptable salts, enantiomers, diastereoisomers, or mixtures thereof, including racemic mixtures, for the use thereof as a drug for the prophylactic and/or curative treatment of drepanocytosis. | 10-29-2015 |
20150307426 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS - Processes for making and using compounds of formula (I): | 10-29-2015 |
20150320730 | GPBP-1 inhibition and its therapeutic use - The present invention provides compositions including anti-tumor agents and inhibitors of Goodpasture antigen binding protein, p21, and ABCC7, and their use in treating cancer. | 11-12-2015 |
20160038471 | TREATMENT OF TAUOPATHIES WITH mGluR5 ANTAGONISTS - The treatment of abnormal hyperphosphorylation of tau in brains of patients with metabotropic glutamate receptor 5 (mGluR5) antagonists. The treatment uses the signaling pathway in which the inhibition of protein phosphatase 2A (PP2A) through phosphorylation of its catalytic subunit PP2Ac at Tyr | 02-11-2016 |
20160075652 | SYNTHETIC ANALOGUES OF XANTHOHUMOL - The present invention relates to novel synthetic analogues of xanthohumol and the use thereof. | 03-17-2016 |
20160144076 | Mesh Fiber Members and Methods for Forming and Using Same for Treating Damaged Biological Tissue - A mesh fiber member having a plurality of biodegradable fibers, the mesh fiber member being configured to induce modulated healing of damaged biological tissue when deployed proximate thereto. The strands comprise an extracellular matrix (ECM) composition or an ECM-mimicking biomaterial composition, such as poly(glycerol sebacate) (PGS), and can include a biodegradable ECM, polymeric or ECM-mimicking biomaterial composition coating. | 05-26-2016 |
20160151340 | BOWEL CLEANSING COMPOSITION | 06-02-2016 |
20160375000 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF MENTAL DISEASE WITH ENHANCED NMDAR FUNCTION - The present invention relates to a pharmaceutical composition for improving a sociability behavior in a patient having a mental disease with an enhanced NMDAR function. | 12-29-2016 |